ANG

ANG Lifesciences India Share Price

₹45.50 +1.15 (2.59%)

21 Nov, 2024 19:09

SIP TrendupStart SIP in ANG

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -8.14%
  • Over 3 Month -2.84%
  • Over 6 Month -17.94%
  • Over 1 Year -30.19%
SIP Lightning

Smart Investing Starts Here Start SIP with ANG Lifesciences India for Steady Growth!

Invest Now

ANG Lifesciences India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

ANG Lifesciences India Financials

ANG Lifesciences India Technicals

EMA & SMA

Current Price
₹45.50
+ 1.15 (2.59%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹46.08
  • 50 Day
  • ₹47.94
  • 100 Day
  • ₹49.94
  • 200 Day
  • ₹54.84

Resistance and Support

45.26 Pivot Speed
  • R3 49.67
  • R2 48.11
  • R1 46.82
  • S1 43.97
  • S2 42.41
  • S3 41.12

What's your outlook on ANG Lifesciences India?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Angel One, trusted by over 2 crore clients, is a leading retail full-service broking house in India. Its Super App offers advanced tools like basket orders and SmartAPI, enabling seamless trading in stocks, mutual funds, IPOs, and more.

Angel One has an operating revenue of Rs. 5,336.44 Cr. on a trailing 12-month basis. An annual revenue growth of 42% is outstanding, Pre-tax margin of 35% is great, ROE of 37% is exceptional. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 21% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 94 which is a GREAT score indicating consistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Finance-Investment Mgmt and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

ANG Lifesciences India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-02-14 Quarterly Results
2023-11-14 Quarterly Results
Date Purpose Remarks
2021-11-04 INTERIM Rs.1.00 per share(10%)Interim Dividend
Date Purpose Remarks
2022-07-14 Bonus Rs.0.00 issue in the ratio of 1:4 of Rs. 10/-
2021-09-23 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-

ANG Lifesciences India F&O

ANG Lifesciences India Shareholding Pattern

35.61%
9.59%
0.87%
12.27%
0%
36.02%
0%

About ANG Lifesciences India

  • NSE Symbol
  • ANG
  • BSE Symbol
  • 540694
  • Chairman & Managing Director
  • Mr. Dinesh D Thakkar
  • ISIN
  • INE236W01016

Similar Stocks to ANG Lifesciences India

ANG Lifesciences India FAQs

ANG Lifesciences India share price is ₹45 As on 21 November, 2024 | 18:55

The Market Cap of ANG Lifesciences India is ₹59.4 Cr As on 21 November, 2024 | 18:55

The P/E ratio of ANG Lifesciences India is -4 As on 21 November, 2024 | 18:55

The PB ratio of ANG Lifesciences India is 0.8 As on 21 November, 2024 | 18:55

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23